secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rallybio Corp (RLYB)
CIK:        0001739410
Form:       8-K
Filed at:   2023-06-29T23:59:59+00:00
Accession:  0000950170-23-030535
Event type: leadership
Sentiment:  neutral
Materiality: 0.75
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rallybio appoints Stephen Uden as CEO effective Aug 1; Martin Mackay becomes Executive Chairman
--------------------------------------------------------------------------------

- Stephen Uden, current President and COO, named CEO effective Aug 1, 2023; will also join the Board.
- Co-founder Martin Mackay transitions from CEO to Executive Chairman, remains full-time employee focusing on strategy and IR.
- Phase 1 multiple dose cohort data for RLYB212 and initial data for RLYB116 expected in Q4 2023.
- Board size increased to 11 directors; Uden appointed as Class II director with term through 2026 annual meeting.
- Uden's base salary stays at $530,000, target bonus 45%; Mackay's compensation unchanged; severance terms similar.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1739410/000095017023030535/0000950170-23-030535-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1739410/000095017023030535/rlyb-20230628.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-030535

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer